MDACC Study No:2013-0706 ( NCT No: NCT02096042)
Title:A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In CD30-Positive Relapsed/Refractory Acute Myeloid Leukemia
Principal Investigator:Nitin Jain
Treatment Agent:5-Azacytidine; Brentuximab Vedotin
Study Status:Closed
Study Description:This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1,
and Phase 2.

The goal of the Pilot Phase is to learn how safe it is to give the study drug
brentuximab vedotin to patients with AML. The goal of Phase 1 is to learn more
about the safety of the combination of brentuximab vedotin with azacytidine.
The goal of Phase 2 is to learn if the combination of brentuximab vedotin and
azacytidine can help to control AML.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:5-Azacytidine
Brentuximab Vedotin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nitin Jain
For Clinical Trial Enrollment:713-745-6080
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults